TNFSF10 and plasma cell myeloma: CAR‐DC cells specifically target multiple myeloma cells overexpressing BCMA receptors. They selectively bind to these malignant cells and enhance TRAIL‐mediated apoptosis, thereby effectively eliminating multiple myeloma cells for therapeutic purposes.